Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avapritinib Maintenance Post-Allo-HSCT in KIT-Mutated AML
NCT06765915Phase 2Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avapritinib in acute myeloid leukemia (AML), sponsored by Ruijin Hospital. Primary endpoint: Cumulative incidence of relapse at 2 years. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
avapritinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06765915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06765915.